Premium
Effects of 3‐Heptyl‐3,4,6‐trimethoxy‐3H‐isobenzofuran‐1‐one alone or/in association with cyclophosphamide on testicular function
Author(s) -
Oliveira Rodrigo Juliano,
CunhaLaura Andréa Luiza,
Gonçalves Caroline Amélia,
Monreal Antônio Carlos Duenhas,
Costa Deiler Sampaio,
Meza Alisson,
Lima Dênis Pires,
Beatriz Adilson,
Amaral Ernani Aloysio,
Auharek Sarah Alves
Publication year - 2020
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.13622
Subject(s) - cyclophosphamide , infertility , chemotherapy , spermatogenesis , testicular cancer , leydig cell , vinblastine , apoptosis , medicine , adverse effect , toxicity , endocrinology , biology , andrology , hormone , biochemistry , genetics , luteinizing hormone , pregnancy
Abstract Chemotherapy for cancer treatment may result in a temporary or long‐term gonadal damage resulting in subfertility or infertility. Cyclophosphamide (CY) is a cytotoxic alkylating agent that has been widely used in the treatment of cancer. Recent studies have shown that synthetic resorcinol lipid AMS35AA (3‐Heptyl‐3,4,6‐trimethoxy‐3H‐isobenzofuran‐1‐one) may be an important adjuvant chemotherapy that potentiates mutagenic damage and increases apoptosis caused by CY. The present study investigates the action of AMS35AA alone or/in association with CY on testicular function. Animals were divided into four groups: (a) control group: received only water; (b) CY group: received 150 μg/g of CY b.w., i.p.; (c) AMS35AA group: received 10 μg/g of AMS35AA b.w., i.p; and (d) associated group: received 10 μg/g of AMS35AA + 150 μg/g of CY b.w., i.p. Four weeks after the treatment, the results showed that testes weight of CY and associated groups decreased. However, the number of Sertoli cell and Leydig cell per testis was similar in control and treated groups. Our findings provide strong evidence that the AMS35AA alone or in CY association is not toxic to spermatogenesis. The absence of toxicity of AMS35AA supports the view that the resorcinolic lipid could be used associated with CY chemotherapy without causing adverse effects to testes function.